Antibody-based inhibition of pathogenic new world hemorrhagic fever mammarenaviruses by steric occlusion of the human transferrin receptor 1 apical domain by Ferrero, Sol et al.
Antibody-Based Inhibition of Pathogenic New World
Hemorrhagic Fever Mammarenaviruses by Steric Occlusion of
the Human Transferrin Receptor 1 Apical Domain
Sol Ferrero,a Maria D. Flores,b Connor Short,b Cecilia A. Vazquez,c,g Lars E. Clark,d James Ziegenbein,b Samantha Zink,b
Daniel Fuentes,b Cristian Payes,a María V. Batto,a Michael Collazo,e Cybele C. García,c,g Jonathan Abraham,d,f Sandra M. Cordo,c
Jose A. Rodriguez,b Gustavo Helgueraa
aLaboratory of Pharmaceutical Biotechnology, Instituto de Biología y Medicina Experimental (IBYME-CONICET), Buenos Aires, Argentina
bDepartment of Chemistry and Biochemistry, UCLA-DOE Institute for Genomics and Proteomics, University of California Los Angeles, Los Angeles, California, USA
cLaboratorio de Virología, Departamento de Química Biológica, Facultad de Ciencias Exactas y Naturales, Universidad de Buenos Aires (UBA), IQUIBICEN, Consejo
Nacional de Investigaciones Científicas y Técnicas (CONICET)-UBA, Ciudad Universitaria, Buenos Aires, Argentina
dDepartment of Microbiology, Blavatnik Institute, Harvard Medical School, Boston, Massachusetts, USA
eDepartment of Biological Chemistry and Department of Chemistry and Biochemistry, University of California Los Angeles, Howard Hughes Medical Institute, UCLA-DOE
Institute for Genomics and Proteomics, Los Angeles, California, USA
fDepartment of Medicine, Division of Infectious Diseases, Brigham and Women’s Hospital, Boston, Massachusetts, USA
gIQUIBICEN, Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET)-UBA, Ciudad Universitaria, Buenos Aires, Argentina
Sol Ferrero and Maria D. Flores contributed equally to this work and share equal right to be listed as principal author. Author order was determined alphabetically.
ABSTRACT Pathogenic clade B New World mammarenaviruses (NWM) can cause
Argentine, Venezuelan, Brazilian, and Bolivian hemorrhagic fevers. Sequence variability
among NWM glycoproteins (GP) poses a challenge to the development of broadly neu-
tralizing therapeutics against the entire clade of viruses. However, blockade of their
shared binding site on the apical domain of human transferrin receptor 1 (hTfR1/CD71)
presents an opportunity for the development of effective and broadly neutralizing thera-
peutics. Here, we demonstrate that the murine monoclonal antibody OKT9, which tar-
gets the apical domain of hTfR1, can sterically block cellular entry by viral particles pre-
senting clade B NWM glycoproteins (GP1-GP2). OKT9 blockade is also effective against
viral particles pseudotyped with glycoproteins of a recently identified pathogenic Sabia-
like virus. With nanomolar affinity for hTfR1, the OKT9 antigen binding fragment (OKT9-
Fab) sterically blocks clade B NWM-GP1s and reduces infectivity of an attenuated strain
of Junin virus. Binding of OKT9 to the hTfR1 ectodomain in its soluble, dimeric state pro-
duces stable assemblies that are observable by negative-stain electron microscopy. A
model of the OKT9-sTfR1 complex, informed by the known crystallographic structure of
sTfR1 and a newly determined structure of the OKT9 antigen binding fragment (Fab),
suggests that OKT9 and the Machupo virus GP1 share a binding site on the hTfR1 apical
domain. The structural basis for this interaction presents a framework for the design and
development of high-affinity, broadly acting agents targeting clade B NWMs.
IMPORTANCE Pathogenic clade B NWMs cause grave infectious diseases, the South
American hemorrhagic fevers. Their etiological agents are Junin (JUNV), Guanarito
(GTOV), Sabiá (SABV), Machupo (MACV), Chapare (CHAV), and a new Sabiá-like (SABV-L)
virus recently identified in Brazil. These are priority A pathogens due to their high infec-
tivity and mortality, their potential for person-to-person transmission, and the limited
availability of effective therapeutics and vaccines to curb their effects. While low homol-
ogy between surface glycoproteins of NWMs foils efforts to develop broadly neutralizing
therapies targeting NWMs, this work provides structural evidence that OKT9, a monoclo-
nal antibody targeting a single NWM glycoprotein binding site on hTfR1, can efficiently
prevent their entry into cells.
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Despite the gravity of South American hemorrhagic fevers (1–3), treatments againstpathogenic New World mammarenaviruses (NWMs) remain limited. Low sequence
homology among the glycoproteins of this family of viruses hinders the development
of broadly neutralizing virus-targeting therapeutics. A vaccine against Argentine hem-
orrhagic fever (AHF) derived from attenuated JUNV strain CANDID#1 is produced in
Argentina and has reduced incidence of the disease, but to date no effective FDA-
approved treatment or vaccine exists against all New World hemorrhagic fevers
(NWHFs) (4). Small molecules have shown limited efficacy against NWHF viruses; the
antiviral favipiravir (T-705) in combination with rivabirin (5) and RNA aptamers are
under investigation but have yet to reach clinical trials (44). Recent efforts have found
success in the development of neutralizing monoclonal antibodies against NWHF
mammarenavirus glycoproteins. However, while virus-neutralizing monoclonal anti-
bodies can mimic important receptor contacts when engaging the glycoprotein of a
particular NWM (6), they show limited or no activity against the glycoproteins of other
members of the NWM family (4, 6).
Despite the low sequence identity between their glycoprotein sequences (25% to
46%), clade B NWMs share routes of entry into human cells. One such example is the
human transferrin receptor (hTfR1), a single-pass transmembrane protein that regu-
lates iron uptake into cells (7). Structural studies have determined the atomic nature
of the interaction of Machupo virus (MACV) GP1 with hTfR1 and revealed a conserved
binding site for clade B NWM GP1 binding on the apical domain of hTfR1 (8). The pu-
tative binding of all members of this clade to the same epitope on hTfR1 makes it an
attractive molecular target for the development of broad-spectrum inhibitors of viral
entry, including antibodies (9). Recombinant monoclonal antibodies have been iden-
tified that exploit this vulnerability by binding hTfR1 and blocking the internalization
of pseudotyped viral particles decorated with Junin (JUNV), Guanarito (GTOV), Sabiá
(SABV), MACV, Chapare (CHAV), and Sabiá (SABV) virus glycoproteins (GP) but not
pseudotyped viral particles expressing glycoproteins from Old World hemorrhagic
fever viruses, such as Lassa virus (LASV) (9). More recently, such antibodies have been
shown to block entry of the North American mammarenavirus AV96010151 into cells,
expanding their potential efficacy against a broader spectrum of NWHF viruses (45).
Likewise, arenacept, a recombinant protein consisting of the apical domain of hTfR1
fused to an Fc domain, is capable of binding GP1 of several NWMs and preventing
pseudotyped virus internalization into cells (10).
While hTfR1-targeting antibodies have demonstrated potential as broadly neutral-
izing therapeutics against clade B NWMs, this strategy faces key challenges. A con-
crete molecular basis for the inhibition of viral entry through hTfR1-targeting anti-
bodies is still lacking. This is due in part to the absence of structures of these
targeting agents bound to hTfR1 despite a large number being discovered and
explored for other therapeutic applications. The murine monoclonal OKT9 was
among the first antibodies shown to recognize hTfR1 in several cell lines and have its
activity explored in a variety of contexts (11–13). We now demonstrate that OKT9 is a
potential blocker of cell entry by clade B NWMs, as it engages an epitope on the api-
cal domain of hTfR1 that is a shared binding site for clade B NWM glycoproteins.
OKT9 prevents cell entry by pseudotyped viral particles with the surface glycopro-
teins of a newly sequenced and lethal Sabiá-like (SABV-L) NWM (14). We also demon-
strate that OKT9 blockade can inhibit the in vitro replication of a competent, albeit
attenuated, strain of JUNV (15). Knowledge that OKT9 blocks the GP1-TfR1 interaction
through steric occlusion presents a mechanistic platform for the development of
broadly active competitive inhibitors of NWHF that target viral entry mediated by
hTfR1.
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The OKT9 variable region binds hTfR1 with nanomolar affinity. Despite the
longstanding characterization of OKT9 as a monoclonal antibody that binds hhTfR1,
we first set out to biochemically assess this interaction using a recombinantly gener-
ated soluble form of hTfR1 with a C-terminal hexahistidine tag that we refer to as
hTfR1 (16). Size-exclusion chromatography (SEC) of hTfR1 yields peaks that elute at col-
umn fractions consistent with monomer and multimer species in solution; sampling of
peak fractions and evaluation by SDS-PAGE shows a single principal band at ;79 kDa,
corresponding to a monomer. Traces for OKT9-Fab alone show a principal peak eluting
at column fractions consistent with a monomer; a 50-kDa band is observed from these
fractions by SDS-PAGE, consistent with the expected molecular weight for a Fab mono-
mer (Fig. 1A). hTfR1 was mixed with OKT9-Fab at a 3:1 molar ratio and incubated for
20min at room temperature to facilitate the formation of a solution-state complex.
Traces of the mixture show a shift of peaks to earlier column fractions compared to the
receptor alone. The peak corresponding to OKT9-Fab alone disappears in traces for the
mixture, indicating a loss of free Fab in solution. This is confirmed by SDS-PAGE of
peak fractions showing a coelution of Fab with TfR1 in early fractions (Fig. 1B).
We evaluated the binding of full-length OKT9 and its proteolytic antigen binding
fragment (OKT9-Fab) to hTfR1 immobilized on a solid surface or in solution. Both OKT9
and OKT9-Fab bound surface-immobilized hTfR1 in a concentration-dependent man-
ner with approximate 50% effective concentration (EC50) values of 0.411 nM (OKT9)
and 3.659 nM (OKT9-Fab) (Fig. 1C). The affinity of OKT9-Fab for hTfR1 was further
assessed by biolayer interferometry (BLI), with various concentrations of full-length
OKT9 exposed to a fixed concentration of hTfR1 immobilized on the biolayer sensor via
an anti-His antibody and assuming a 1:1 interaction between Fab and receptor.
Averaging across four biolayer cycles produced an equilibrium dissociation constant of
4.8 nM for the interaction between OKT9-Fab and hTfR1 (Fig. 1D). Rate constants for
each cycle are shown in Table 1. Biolayer interferometry was also used to directly eval-
uate competition between OKT9-Fab and a MACV GP1-Fc fusion protein for binding to
a soluble form of hTfR1 (sTfR1) in solution (Fig. 1E). MACV GP1-Fc bound to a biosensor
surface was able to efficiently bind hTfR1, but this binding was abrogated in the pres-
ence of OKT9-Fab. By comparison, transferrin, which does not compete with MACV for
binding to hTfR1 (7), had no effect on hTfR1 binding to immobilized MACV GP1-Fc.
These results suggest that OKT9 and MACV GP1 bind overlapping sites on hTfR1.
OKT9 and OKT9-Fab block cellular entry of pseudotyped viruses presenting
clade B NWM glycoproteins and a nonpathogenic strain of JUNV. Entry of pseudo-
typed viruses presenting clade B NWM glycoproteins into cells expressing hTfR1 was
monitored through their expression of eGFP upon cellular entry, serving as a platform
to assess the effectiveness of hTfR1 blockade by OKT9 (7). In this context, both OKT9
and OKT9-Fab inhibit the internalization of clade B NWM glycoprotein-presenting
pseudovirus into HEK-293T cells. Unperturbed pseudovirus presenting glycoproteins
from JUNV, SABV, MACV, GTOV, CHAV, SABV-L, and LASV all entered cells and pro-
duced green fluorescence. Cultured cells preincubated with 100 nM OKT9-Fab, OKT9,
or a non-TfR1 specific antibody were exposed to JUNV, MACV, SABV-L, and LASV pseu-
dovirus. Wide-field fluorescence images of cells treated with OKT9 or OKT9-Fab
showed significantly lower levels of eGFP expression than cells without antibody treat-
ment (Fig. 2A). While treatment with anti-TfR1 antibodies has been associated with
downregulation of cell surface TfR1 (17), HEK-293T cells incubated with 100mM OKT9
or OKT9-Fab for 48 h showed no decrease in cell binding of Tf-TMR. Fluorescence mi-
croscopy images showed similar binding of Tf to the cell surface across all conditions,
as indicated by colocalization with the membrane-targeting fluorophore DiO (Fig. 2B).
Changes in pseudovirus internalization were quantified by flow cytometry (Fig. 2C and
D), showing decreased internalization of MACV, JUNV, and SABV-L in the presence of
OKT9 and OKT9-Fab. Internalization of LASV pseudovirus was unaffected by OKT9 or
OKT9-Fab, while a non-TfR1 specific antibody did not affect pseudovirus internalization
(Fig. 2C and D). A 30-min preincubation of cells with OKT9 showed dose-dependent
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FIG 1 Characterization of OKT9 binding to hTfR1. (A) Formation of an hTfR1-OKT9 complex
evaluated by SEC coelution. Samples include hTfR1 (purple), OKT9-Fab (blue), and sTfR11OKT9-Fab
(maroon). An overlay of all traces is shown for comparison. Gray bars indicate collected fractions.
The red star denotes the expected peak fraction for OKT9-Fab alone. (B) SDS-PAGE of fractions
collected from isolated and complex SEC runs. On the left is shown the SDS-PAGE of the SEC
fractions of the hTfR1 run, in the center the fractions of the OKT9-Fab run, and on the right the
fractions of the complex. Colored boxes indicate the presence of the protein of interest, coordinated
(Continued on next page)
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inhibition of pseudovirus internalization (Fig. 2E), yielding 50% inhibitory concentra-
tion (IC50) values of 0.329 nM (JUNV), 0.234 nM (SABV), 1.415 nM (MACV), 0.362 nM
(GTOV), 0.274 nM (CHAV), and 0.632 nM (SABV-L) (Table 2).
Both OKT9 and OKT9-Fab blocked entry of a replicating strain of JUNV into A549
cells. Viral replication was measured 24 h postinfection by quantifying viral particles
released to the supernatants and by analyzing viral RNA levels in infected cell mono-
layers. Cultures treated with OKT9 or OKT9-Fab produced smaller amounts of viral par-
ticles, as determined by plaque assays (Fig. 2F), and also had lower levels of viral RNA,
as measured by reverse transcription-quantitative PCR (RT-qPCR) (Fig. 2G), compared
to the nontreated control. These results suggest that both OKT9 and OKT9-Fab blocked
viral entry, reducing the cell susceptibility to this virus and, thus, preventing cell infec-
tion. The decrease in viral replication is specific, since cultures treated with an IgG that
did not target TfR1 showed no significant differences from buffer control.
The crystallographic structure of OKT9-Fab. A crystal structure of OKT9-Fab was
determined to 2.0-Å resolution by microfocal X-ray diffraction (Table 3). The molecule
crystallized with space group P21212 with a single molecule in the asymmetric unit.
The structure was determined by molecular replacement using chains from PDB entries
4Q0X and 4OTX. Sequences for the variable light and heavy chains, determined by
sequencing of their genomic loci from the OKT9 hybridoma cell line (Fig. 3A), were
used as guides during model building and data refinement (Fig. 3B).
The overall structure of OKT9-Fab resembles a canonical murine IgG1 variable region. All
three complementary determining regions (CDRs) in the heavy and light chains were
resolved (Fig. 3B). Their sequences were identified as CDRL1 QSLFNSANQENY (27-38), CDRL2
WAS (56-58), CDRL3 QNDYSYPLT (95-103), CDRH1 GYTFTNYY (26-33), CDRH2 IYPGDGNT (51-
58), and CDRH3 ARDNSGYVGFPY (97-108). The constant heavy-chain region spanning from
A136 to T139 showed poor density that precluded building during refinement and
remained unbuilt in the final structure. Of greatest relevance was missing density for residue
Y103 in CDR 3 of the heavy chain (Fig. 3B). Its side chain could not be placed during refine-
ment and was omitted from our deposited structure but was included in subsequent com-
putational analyses.
OKT9 binds hTfR1 to form closed bivalent complexes identifiable by electron
microscopy. To evaluate the basis for inhibition of cellular internalization of NWM by
OKT9 targeting of hTfR1, we sought to reveal the mode of interaction between full-length
TABLE 1 Kinetics analysis of OKT9-Fab binding to hTfR1 via bilayer interferometrya
Cycle KD (M) KD error ka (1/ms) ka error Kdis (1/s) Kdis error Full X2 Full R2
A 4.76e209 8.32e211 2.38e105 1.68e103 1.14e203 1.81e205 0.0728 0.9951
B 4.82e209 8.00e211 2.50e105 1.73e103 1.20e203 1.82e205 0.0730 0.9954
C 4.90e209 8.15e211 2.54e105 1.81e103 1.25e203 1.87e205 0.0767 0.9952
D 4.78e209 7.59e211 2.62e105 1.78e103 1.25e203 1.80e205 0.0695 0.9956
aKD, equilibrium dissociation constant; ka, association rate constant; Kdis, dissociation rate constant.
FIG 1 Legend (Continued)
with the color used in SEC traces. The red arrow denotes the expected band for OKT9-Fab. (C) ELISA
binding of OKT9 to hTfR1. An indirect ELISA was performed decorating the plate with sTfR1 and
then incubating with different concentrations of OKT9-Fab and OKT9. Anti-mouse IgG conjugated to
HRP was used as a secondary antibody. The EC50 calculated over the normalized OD450 for OKT9 was
0.411 nM with a 95% confidence interval (CI) of 0.213 to 0.633, and for OKT9-Fab the EC50 was
3.695 nM with a 95% CI of 2.463 to 6.028. (D) Kinetics of OKT9-Fab interaction with hTfR1
immobilized on a biosensor surface. The receptor was exposed to increasing concentrations of
OKT9-Fab as labeled (31.3 nM, 62.5 nM, 125 nM, and 250 nM). One hundred eighty seconds of
biolayer recordings show binding and dissociation. (E) Assessment of OKT9-Fab and MACV GP1-Fc
for binding to sTfR1 by biolayer interferometry. MACV GP1-Fc immobilized onto anti-human Fc
biosensor tips and incubated with sTfR1 (top left) or buffer alone (bottom left), sTfR1 in complex
with OKT9-Fab (top center), OKT9-Fab alone (bottom center), sTR1 in complex with transferrin (top
right), or transferrin alone (bottom right). The arrows indicate the time points at which the indicated
proteins were added and the dissociation step. The data are representative of two replicates for
each of the experimental conditions shown.
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FIG 2 Inhibition of internalization of NWHF pseudovirus by OKT9. (A) Fluorescence microscopy images of HEK-293T cells. The images were
taken from the inhibition of JUNV, MACV, SABV-L, and LASV pseudovirus internalization assays mentioned for panel B: pseudovirus 1 buffer
control, pseudovirus1 100 nM OKT9, pseudovirus1 100 nM OKT9-Fab, and pseudovirus1 100 nM anti-EGFR as a nonrelevant antibody
control. The reference bar indicates 50mm. (B) Fluorescence microscopy of HEK-293T cells treated 48 h with buffer control, 100 nM OKT9,
(Continued on next page)
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OKT9 and hTfR1. A solution containing OKT9 and hTfR1 was drop-cast onto electron mi-
croscopy grids and negatively stained with uranyl acetate. Use of an equimolar ratio of
OKT9 to hTfR1 allowed for the formation of stable, homogenous assemblies; complexes
with a prominent diamond-shaped structure were identified (Fig. 3C). Imaging of these
grids at various tilt angles, ranging from 0 to 45 degrees, circumvented the preferred orien-
tation of the flat, diamond-like assemblies on the grid. Combining images across all tilts
revealed multimeric complexes of receptor and OKT9 that could be subclassified using sin-
gle-particle methods (Fig. 3C). A low-resolution structure of OKT9 in complex with hTfR1
was determined from these images. Particles contributing to the best classes were used to
generate an ab initiomodel used for further refinement (Fig. 3E). Despite low particle count
and preferred particle orientations, the refined three-dimensional (3D) density determined
from these data revealed the binding interface between hTfR1 and OKT9 (Fig. 4A). The Fc
region of OKT9 could not be identified in 2D averages or in the final 3D density, likely due
to the flexibility of the hinge region (Fig. 3C). The resulting density showed sufficient reso-
lution to suggest the relative orientation of the OKT9 variable regions with respect to the
apical domain of hTfR1.
Computational prediction of OKT9-Fab binding footprint on hTfR1. We vali-
dated the configuration of OKT9 relative to hTfR1 in our reconstruction by comparing
the reconstructed density to a series of docked models generated using the web-based
server ClusPro 2.0 (18). For this, we relied on the known structure of hTfR1 (PDB entry
3KAS) and our crystal structure of OKT9-Fab. We used ClusPro in antibody mode, where
CDR residues and the framework surface residues were excluded in the repulsion mask
of the Fab. An attraction mask was generated on the surface residues of hTfR1 based
on the reconstructed 3D density of the OKT9-TfR1 complex. Lastly, a repulsion mask
was generated to exclude other residues on hTfR1 that flanked this area. ClusPro gen-
erated 10 docked models (Fig. 4B). OKT9-Fab models docked onto hTfR1 were fit onto
the 3D density maps for the OKT9-hTfR1 complex using a rigid-body procedure in
Chimera. This procedure yielded two top models that matched the relative orientation
FIG 2 Legend (Continued)
100 nM OKT9-Fab, or 100 nM anti-EGFR, labeled with the DiO membrane dye (green), and incubated for 30 s with transferrin-TMR (red). The
reference bar indicates 34mm. (C) Flow cytometry dot plot analysis of JUNV, MACV, SABV-L, and LASV pseudovirus internalization in HEK-
293T cells showing eGFP expression in the absence and presence of 100 nM OKT9, OKT9-Fab, and anti-EGFR. In the case of MACV, JUNV, and
SABV-L, a reduction of the percent eGFP-positive events occurs in the presence of OKT9 and OKT9-Fab compared to buffer control and the
nonrelevant antibody. In the case of LASV, similar levels of eGFP events are observed independently of the treatment. The percentages of
eGFP-positive events are indicated inside the gates. (D) Inhibition of JUNV, MACV, and SABV-L pseudovirus internalization. Relative entry rate
of JUNV, MACV, the recently reported SABV-L, and control LASV pseudovirus in HEK-293T cells was quantified in the presence of 100 nM
OKT9-Fab, 100 nM OKT9, and 100 nM anti-EGFR. The data were 100% normalized with the cells without treatment, and the significant
differences are indicated by comparing Fab OKT9, OKT9, and the negative-control anti-EGFR versus no treatment (*, P , 0.005, Student's t
test for unpaired data of triplicate determinations). (E) Relative entry rate of pseudoviruses decorated with the GP1/GP2 complex of SABV,
JUNV, MACV, GTOV, CHAV, SABV-L, and LASV to HEK-293T cells in the presence of OKT9 (0.01 to 100 nM). Pseudoviruses were loaded with
an eGFP expression vector to express once internalized. After 48 h, the cells were fixed and the percentage of positive internalization events
quantified by flow cytometry. The data are expressed as the means 6 standard deviations (SD) from the sample. The data were normalized
to 100% with the cells without treatment. (F) OKT9 and OKT9-Fab inhibit the infectivity of JUNV IV4454 virus strain. A549 cells were
preincubated for 1 h with 200 nM OKT9, OKT9-Fab, anti-EGFR, or medium alone (control) and then infected with JUNV at an MOI of 0.01.
After 1 h of incubation, viral inocula were replaced with the respective antibody-supplemented medium or medium alone, and 24 h
postinfection, total JUNV production in A549 cell supernatants was measured using a PFU assay in Vero cells. The graph shows means 6 SD
from a representative experiment (from four independent experiments). The statistical analysis performed was ANOVA followed by Duncan’s
test (**, P , 0.05). (G) Set of 200 nM OKT9-, OKT9-Fab-, anti-EGFR-, or medium alone (control)-treated A549 cells monolayers was harvested
with TRIzol for RNA extraction 18 h postinfection with JUNV IV4454. Viral RNA (z gene) was quantified using RT-PCR, using actin as a
housekeeping gene. The graph shows means 6 SD from two independent experiments. The statistical analysis performed was ANOVA
followed by Dunnett’s test (*, P , 0.0001).
TABLE 2 Analysis of NWM pseudovirus inhibition of internalization by OKT9
Parameter SABV JUNV MACV GTOV SABV-L CHAV
IC50a (nM) 0.2339 0.3294 1.4150 0.3622 0.6320 0.2740
95% CI, IC50 (nM) 0.1393 to 0.3954 0.1019 to 0.9872 0.7233 to 2.865 0.2056 to 0.6384 0.4270 to 0.9354 0.2213 to 0.3399
R2 0.9609 0.8658 0.9311 0.9434 0.9803 0.9948
aThe fitting model used is Y = (bottom1 top-bottom)/(11 10(X-LogIC50)), where IC50 is the concentration of OKT9 that gives a response halfway between bottom and top, and
top and bottom are plateaus in the units of the y axis.
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of 3D density for OKT9-Fab with respect to hTfR1 and best fit the 3D antibody density
(Fig. 4C). While the resolution of this 3D model does not allow for the identification of
residue-level interactions, the overall binding footprint of OKT9 on hTfR1 is identifiable
(Fig. 4D). Analysis of the putative binding interface for the best of these models shows
a significant overlap of the binding site for MACV GP1 on hTfR1, with both OKT9 and
MACV GP1 competing to bind an exposed loop in the hTfR1 apical domain (Fig. 4E).
DISCUSSION
The treatment of infectious diseases caused by viral agents with high sequence and
structural diversity presents a challenge for targeted therapy (19). Broadly neutralizing
antiviral antibodies are scarce given the sequence diversity of viral epitopes and their
constant evolutionary pressure; this applies to NWMs. In contrast, strategies that target
a host receptor, such as hTfR1, are appealing given its cell surface accessibility, low
sequence variability across populations, and well-characterized structure and physiol-
ogy (20). The identification of a single conserved epitope on hTfR1 as a shared binding
site for clade B NWMs and the determination of a crystallographic structure of MACV
GP1 bound to the conserved epitope have illuminated avenues for NWM neutraliza-
tion. This knowledge has already enabled the isolation and characterization of various
NWM neutralizing antibodies (4, 6, 7, 21).
Antibodies capable of neutralizing or preventing cell entry of more than one NWM
have targeted either the site of hTfR1 binding on MACV and JUNV GP1 or the hTfR1 ap-
ical domain itself (9, 22). Taking advantage of this opportunity for broad NWM neutrali-
zation by hTfR1 targeting (8), we establish the well-known, hTfR1-targeting murine
monoclonal antibody OKT9 as a framework for future development of NWM-neutraliz-
ing agents that reduce cellular uptake of NWMs. OKT9 competes with only one known
natural ligand, heavy-chain ferritin (Fe) (Fig. 4E) (23). However, homeostatic alterations
resulting from this competition are unclear given that iron uptake via ferritin is not a
principal mechanism of iron uptake into cells. Importantly, OKT9 is not expected to
interfere with transferrin (Tf) binding to hTfR1, as that interaction relies entirely on the
membrane, proximal helical, and protease-like domains (Fig. 4E) (20). Moreover,
TABLE 3 Data collection and refinement statistics for OKT9-Fab
Parameter Value
Data collection
Space group P 21 21 2
Cell constants a, b, c (Å) 94.66, 113.96, 40.84
Cell constants a, b ,g (°) 90, 90, 90
Resolution (Å) 48.82–2.00
% Data completeness 99.2 (48.82–2.00)
Mean I/s (I) 15.66 (3.12)
Wilson B-factor (Å2) 34.78
Refinement
No. of total reflections 154,169
No. of unique reflections 30,478
CC1/2 99.9
No. of reflections used in refinement 30,471
No. of reflections used for Rfree 3,048
Rwork 0.2164
Rfree 0.2535
No. of nonhydrogen atoms 3,475
No. of protein residues 433
Wavelength (Å) 0.979
Ramachandran plot (%)
Residues in favored region 97.65
Residues in allowed region 2.35
Residues in outlier region 0
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despite previous reports of anti-TfR1 antibodies depleting cell surface TfR1 by altering
its recycling and inducing its accumulation and degradation in late endosomes or lyso-
somes (17), 48-h treatment of HEK-293T cells with OKT9 or OKT9-Fab did not signifi-
cantly alter cell surface binding of Tf.
FIG 3 Crystallographic structure of OKT9-Fab and visualization of the hTfR1-OKT9 complex. (A) Amino
acid sequence of OKT9 heavy-chain (top) and light-chain (bottom) variable region. In blue are the
heavy-chain CDRs H1, H2, and H3 and in light blue the light-chain CDRs L1, L2, and L3. (B) X-ray
crystallographic structure of OKT9-Fab with heavy chain colored in slate and light chain in cyan.
Loops corresponding to variable light chain CDRs are labeled L1, L2, and L3, and CDRs for the
variable heavy chain are labeled H1, H2, and H3, where unmodeled regions are shown as dashed
lines. An unmodeled tyrosine residue in CDRH3 is shown in white. (C) Micrograph of negatively
stained sample containing hTfR1-OKT9 complex. Red triangles indicate particles selected for 2D
classification (scale bar, 50 nm). (D) Representative particles and 2D class averages of negatively
stained hTfR1-OKT9 complexes on ultrathin carbon (scale bar, 200Å). (E) Projections of 3D hTfR1-
OKT9 complex density along two orthogonal directions. 3D density was obtained by ab initio
reconstruction from negative-stain images of the complex.
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The variable region of OKT9 binds hTfR1 with nanomolar affinity, allowing full-
length OKT9 to inhibit cellular entry by NWM with nanomolar IC50. This efficient inhibi-
tion of NWM internalization is enabled by the high overall avidity of full-length OKT9,
with an EC50 value an order of magnitude better than that for OKT9-Fab. The affinity
estimated for the binding of OKT9-Fab to hTfR1 is on par with that previously reported
for other TfR1-binding antibodies, including ch128.1, with equilibrium dissociation
FIG 4 Docking model of hTfR1-OKT9 complex and relationship to natural ligands and human
pathogen molecular ligands. (A) Isosurface rendering of hTfR1-OKT9 3D density map with an
estimated resolution of 11 Å. Inset shows a well-resolved region of the 3D density, corresponding to a
monomeric transferrin receptor bound by an OKT9-Fab. Front (left) and side (right) views are shown.
(B) Front views of all 10 ClusPro-generated models using OKT9-Fab and 3KAS hTfR1 apical domain
monomer (white). Best-fit models used for analysis are highlighted in red; other models are shown in
hues of blue. (C) Overlay of ClusPro generated model using OKT9-Fab and crystal structure PDB entry
3KAS with hTfR1-OKT9 3D density. (D) Surface representation of the 3KAS apical domain (dark gray)
colored to illustrate the binding interface with MACV GP1 protein (salmon), OKT9-Fab model (blue),
or both (black). (E, top) Transferrin receptor (gray) bound to natural ligands (transferrin, PDB entry
1SUV; hereditary hemochromatosis factor [HFE] [43], PDB entry 1DE4; and ferritin, PDB entry 6GSR).
(Bottom) Transferrin receptor bound to OKT9-Fabs and human pathogens (MACV-GP1, PDB entry
3KAS; P. vivax, PDB entry 6D04).
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constant (KD) values of 4.82 nM and 5.7 nM, respectively (9). OKT9-Fab also binds hTfR1
with equal or greater affinity than virus-neutralizing antibody variable fragments tar-
geting GP1 of JUNV (5 nM) and MACV (16.3 nM) (22). These comparisons illustrate the
opportunity for high-affinity inhibition of viral entry by targeting hTfR1, provided the
targeting agent effectively precludes binding of NWM GP1 to the receptor. The po-
tency of OKT9 viral entry inhibition is further demonstrated on a competent attenuated
JUNV, where treatment with the antibody led to reduced plaque formation and viral
detection by RT-PCR. This approach succeeded despite the potential for non-TfR1-
mediated viral entry, possibly involving C-type lectins DC-SIGN/L-SIGN (24, 25), the
phosphatidylserine receptors Axl (26), TIM-1 (27), or fluid-phase uptake.
Use of single variable-domain antibodies or antibody fragments is warranted when
potent enough to act within the timescale of their half-life. Antibody fragments are
especially preferable when their corresponding full-length antibody is associated with
a risk of immunotoxic effects in humans (28). For these reasons, use of OKT9-Fab could
be favored over its full-length counterpart given a history of potential homeostatic dys-
regulation by full-length OKT9: incubation of the erythroleukemia cell line K562 to full-
length OKT9 induces cellular redistribution and increased degradation of TfR1 (29).
Potential autoimmune reactions add to concerns over homeostatic dysregulation
induced by full-length OKT9, as with other full-length antibodies. The superior avidity
of full-length OKT9 over OKT9-Fab can also be a detriment, as has been observed in
relation to transcytosis across the blood-brain barrier (30). These concerns are espe-
cially pressing for hTfR1 targeting given its ubiquitous expression across tissue types.
However, several of these potential issues can be mitigated by engineering of full-
length antibodies to suppress binding of immune effector molecules to their Fc region
and/or introducing mutations that reduce the affinity of each variable region.
The overall site of interaction between the OKT9 variable region and the apical do-
main of hTfR1 stands near a previously identified loop thought to be a key determinant
for MACV GP1 binding on hTfR1. In fact, based on negative-stain single-particle elec-
tron microscopy and computational docking models, residues D204, Y211, and N348
on hTfR1 are hypothesized to be bound by both MACV GP1 and OKT9 and are key
determinants of zoonotic transmission across arenaviruses (31). Direct competitive in-
hibition of NWM GP1 binding to hTfR1 by the OKT9-Fab is supported by biolayer inter-
ferometry-based competition assays and presents a molecular framework for dissect-
ing NWM blockade by hTfR1-targeting antibodies. Therefore, hTfR1 blockade by the
OKT9 variable region alone is sufficient for blocking viral entry and permits the discov-
ery of new NWM viruses that utilize TfR1 as a port of entry into human cells. We dem-
onstrate this by investigating the recently reported and lethal Sabia variant (SABV-L),
whose genome sequence has been determined, and its S segments coding for its gly-
coproteins share 87% homology with those of SABV strain SPH114202 (14). OKT9
blockade of GP-mediated cellular entry of this new virus not only confirms its use of
hTfR1 as a portal of entry into human cells but also could inform on the impact of
hTfR1 binding by other pathogens, such as the malaria parasite Plasmodium vivax (Fig.
4E) (32). Importantly, the unique geometry of the ternary complex formed by dimeric
receptor and OKT9 in solution suggest efficient steric occlusion of the hTfR1 apical do-
main with limited cross-linking at the cell surface.
Monoclonal antibody-based therapies are now front-line treatments for a variety of
diseases. Only four monoclonal antibodies have been FDA approved to treat an infec-
tious disease. Three of these directly target infectious pathogens, including palivizu-
mab for respiratory syncytial virus prophylaxis (46) and raxibacumab and obiltoxaxi-
mab for treatment of inhalational anthrax (33, 34). In contrast, ibalizumab targets CD4
to block the entry of HIV-1 into human cells (35). Because of the rare occurrence of
NWHFs as well as their relatively short manifestation in humans, broadly neutralizing
antibodies represent feasible antiviral therapeutics for existing and emerging clade B
NWMs. Our approach further enables a possible route to treatment for those infected
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or at risk of getting infected by hemorrhagic fever viruses that share hTfR1 as a host re-
ceptor, including viral strains that are yet to be identified.
MATERIALS ANDMETHODS
OKT9 IgG1 production. Murine hybridomas expressing the monoclonal antibody OKT9 were
obtained from the ATCC (catalog number CRL-8021). Cultures initially grew in Iscove’s modified
Dulbecco’s medium (IMDM) supplemented with fetal bovine serum (FBS) (10%), GlutaMAX, and penicil-
lin-streptomycin. Once sufficiently proliferated, the cells were passed to 2-liter roller bottles and weaned
from FBS dependence using increasing volumes of SFM (Gibco, USA) before the medium was harvested.
Cells were spun down, and the supernatant was filtered by gravity filtration against cellulose paper
(Millipore, USA) to remove any large particulate matter. This was then passed through a 0.22-mm
Millipore filter, and the clarified medium was purified by affinity chromatography using a protein G col-
umn HiTrap protein G HP (GE LifeSciences, USA) equilibrated to Tris-buffered saline (TBS) with 200mM
NaCl at pH 7.4. The OKT9 was eluted using a gradient of TBS with 100mM glycine and 200mM NaCl at
pH 2.6; 100ml of 1 M TBS at pH 9.0 was added to each fraction. These fractions were analyzed by SDS-
PAGE, and the purest samples were consolidated and concentrated to ;200 to 500ml using an Amicon
Ultra-4 10K centrifugal filter device (Millipore, USA). The resulting protein was further purified via SEC
using an Enrich SEC 650 10- by 300-mm column (Bio-Rad, USA) connected to an NGC Quest 100 chroma-
tography system instrument (Bio-Rad, USA) equilibrated with TBS. SEC fractions were analyzed by SDS-
PAGE and the purest bands were concentrated using an Amicon Ultra-4 10K centrifugal filter device to
;500ml.
OKT9-Fab production. Purified OKT9 was digested with ficin using the mouse IgG1 Fab and F(ab)2
preparation kit (Pierce, Thermo Scientific, USA) according to the manufacturer’s instructions. After diges-
tion, the sample was purified by SEC using an Enrich SEC 650 10- by 300-mm column (Bio-Rad, USA) and
NGC Quest 100 chromatography system chromatography equipment (Bio-Rad, USA) equilibrated with
TBS. These fractions were collected and analyzed by SDS-PAGE to confirm purity and integrity. Fractions
were subsequently concentrated to;100ml using an Amicon Ultra-4 10K centrifugal filter device for use
in crystallization trays.
OKT9 variable region sequence analysis. OKT9 heavy- and light-chain variable region residue com-
positions were determined using mRNA isolated from the hybridoma cell line subjected to RT-PCR with
mouse-specific primer sets to amplify the target regions by using a proprietary sequencing procedure
(LakePharma, USA).
Production and purification of human sTfR1. Baby hamster kidney (BHK) cells expressing the histi-
dine-tagged soluble extracellular domain of human TfR1 (sTfR1) were cultured at 37°C in IMDM with 1
GlutaMAX and 1 penicillin-streptomycin antibiotic mixture and certified 10% fetal bovine serum
(Thermo Fisher, USA). BHK cells were trypsinized with TrypLE express (Thermo Fisher, USA), centrifuged,
and replated after harvest of the sTfR1-containing supernatant. Supernatant was clarified with a 0.22-
mm Millipore vacuum filter and passed through a His trap (GE Healthcare, Millipore, USA) column via fast
protein liquid chromatography (FPLC) on a BioLogicDuoFlow (Bio-Rad, USA). The column was washed
with a 90:10 mixture of TBS (250mM NaCl, 20mM Tris, pH 7.4) and imidazole buffers (250mM NaCl,
20mM Tris, 500mM imidazole) and then eluted via a gradient of increasing imidazole in TBS. Elution
fractions were analyzed via SDS-PAGE, and similar samples were pooled and further purified via an
Enrich SEC 650 10- by 300-mm column (Bio-Rad, USA) and NGC Quest 100 chromatography system chro-
matography equipment (Bio-Rad, USA).
Size exclusion chromatography of OKT9-Fab alone and in complex with soluble human TfR1.
Three hundred micrograms of OKT9-Fab in 500 ml of TBS (50mM Tris, 150mM NaCl, pH 7.6) was injected
into a 2-ml loop of a medium-pressure liquid chromatography system (NGC; Bio-Rad, USA) and run
through an Enrich SEC 650 column (Bio-Rad, USA) using TBS at a flow rate of 0.8ml/min. A similar proce-
dure was performed using 900mg of sTfR1 alone. A complex of sTfR1 and OKT9-Fab was allowed to
form by mixing their solutions at a 3:1 molar ratio of receptor to Fab, followed by incubation at room
temperature for 20min prior to loading into the injection loop. All fractions were collected and analyzed
by SDS-PAGE: 15 ml of each sample was added to 3.5 ml of NuPAGE LDS sample buffer, heated to 98°C
for 10min before being loaded into a precast NuPAGE 4 to 12% bis-acrylamide gel; sizing was analyzed
against a See Blue 2 protein standard. Samples were run for 1 h at 100 V and then stained with
SimplyBlue SafeStain before being imaged on an AzureBiosystems 300c gel imager using the
AzureBiosystems gel analysis software. Analysis of gel images was performed in ImageJ.
Binding of OKT9 to human sTfR1 by ELISA. A 96-well plate was covered with 50ml/well of a 1.5-
mg/ml solution of human sTfR1 in carbonate buffer (0.015 M Na2CO3, 0.035 M NaHCO3, pH 9.3) for 16 h
at 4°C. The plate was washed 3 times with 200ml/well phosphate-buffered saline (PBS), 0.05% Tween 20;
200ml of blocking solution (5% skim milk powder, 1% bovine serum albumin (BSA), and 0.02% sodium
azide in PBS, pH 7.4) was added to each well and incubated for 1 h at room temperature. The plate was
then washed 3 times with 200ml/well of PBS, 0.05% Tween 20, and 50ml/well of OKT9 (0.025 to 25.8 nM)
or OKT9-Fab (0.077 to 76.9 nM) was added to the wells and incubated for 2 h at room temperature. At
the end of the incubation time, the plate was washed 3 times with 200ml/well of PBS, 0.05% Tween 20
and incubated with an anti-mouse IgG horseradish peroxidase (Vector Laboratories) (1:2,000) in a 1:3
dilution of blocking solution for 1 h at 37°C. The plate was then washed 4 times with 200ml/well of PBS,
0.05% Tween 20 and 80ml/well of TMB substrate solution (BD Biosciences) was added and incubated for
30 to 45min at room temperature. The reaction was stopped with 80ml/well of 2 M H2SO4, and the plate
was read by absorbance at an optical density at 450 nm with an enzyme-linked immunosorbent assay
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(ELISA) plate reader (Thermo Scientific, USA). EC50 values were obtained by nonlinear regression fitting
to a variable slope, four-parameter dose-response model using GraphPad Prism 8 (www.graphpad.com).
Binding analysis of OKT9 to human sTfR1 by BLI. All BLI assays were performed on a ForteBio
Octet 96RED at a volume for all the solutions of 200ml/well, with agitation set to 1,000 rpm at 30°C in
solid black 96-well plates (Greiner, USA). HIS1K (Anti-Penta-HIS, USA) probes were equilibrated for 600 s
in TBS, pH 7.6 (50mM Tris-Cl, pH 7.6, 150mM NaCl), prior to sample loading; 100mg/ml sTfR1-His ligand
was loaded for 60 s, followed by a biosensor baseline equilibration step in TBS for 60 s. Typical capture
levels were between 0.4 and 0.5 nm and variability within a row of eight tips did not exceed 0.1 nm.
Loading was followed by a 60-s association step, during which probes were exposed to OKT9-Fab at
concentrations of 250 nM, 125 nM, and 62.5 nM in TBS. Dissociation of Fab was performed in TBS for 900
s. A similar experiment was performed in which 2-fold dilutions from 857.1mg/ml to 13.4mg/ml sTfR1-
His were immobilized to HIS1K probes for 90 s, followed by a baseline equilibration step in TBS for 90 s.
Association of OKT9-Fab at 70 nM for 60 s was next, followed by dissociation in TBS buffer for 600 s.
Data analysis and curve fitting were conducted using Octet 96RED analysis software. Correction of
any systematic baseline drift was achieved by subtracting the shift recorded for a reference sensor
loaded without sTfR1-His and incubated with OKT9-Fab. All data were filtered using the Savitzky-Golay
algorithm and fitted with binding equations that assumed a 1:1 interaction. Global nonlinear least-
squares fitting was performed on data sets that included association and dissociation steps.
MACV GP1-Fc BLI competition assay. The soluble human transferrin receptor 1 (sTfR1) for these
studies was expressed in HEK293S cells. The ectodomain of human transferrin receptor 1 (GenBank
accession no. NM_003234.3, residues 121 to 760) was cloned into the pHLsec expression vector down-
stream of the pHLsec (36) secretion signal. sTfR1 was transfected in HEK293S GnTI2/2 cells (ATCC CRL-
3022TM) using linear polyethylenimine (PEI). HEK293S GnTI2/2 cells were cultured as suspension cells in
FreeStyle 293 expression medium (Gibco, Thermo Scientific, USA) supplemented with 2% (vol/vol) ultra-
low IgG FBS (Thermo Fisher, USA) and penicillin-streptomycin. Supernatant was harvested 72 h post-
transfection. sTfR1 was purified by affinity chromatography using human transferrin-coupled Sepharose
as previously described (8, 37, 38) and eluted in buffer containing 2 M potassium chloride and 50mM
HEPES (pH 7.5). sTfR1 was further purified by size-exclusion chromatography on a Superdex 200 increase
column (GE Healthcare Life Sciences, USA), eluting at the expected retention time. DNA encoding the
MACV GP1 subunit (GenBank accession no. NC_005078, residues 87 to 250) was cloned into a pVRC8400
vector containing human IgG Fc (a gift from Aaron Schmidt). The resulting vector was transfected in
HEK293T cells grown in suspension. The MACV GP1-Fc fusion protein was purified by protein A affinity
purification according to the manufacturer’s protocol (Thermo Fisher Scientific), followed by size-exclu-
sion chromatography on a Superdex 200 increase column. The assay was performed using an Octet
RED96 system (ForteBio, USA). MACV GP1-Fc was loaded onto anti-human IgG Fc capture biosensor tips
(ForteBio, USA) at 17 nM for 100 s in kinetic buffer (PBS containing 0.02% [vol/vol] Tween and 0.1% BSA),
followed by a baseline measurement taken for 120 s. Next, sTfR1 at 1.5mM, sTfR1 at 1.5mM plus OKT-9
at 2mM, or sTfR1 at 1.5mM plus transferrin at 2mM were associated for 300 s. The sensor tip was then
placed in kinetic buffer for 300 s for a subsequent dissociation step.
Generation of pseudotyped virus presenting NWHF glycoproteins. The procedures and vectors
used to make the pseudoviruses used here were described previously (7). Briefly, pseudotyped virus par-
ticles presenting the surface glycoproteins of JUNV, MACV, CHAV, GTOV, SABV, SABV-L, and LASV were
generated by cotransfecting HEK-293T cells with vectors for the expression of the polyprotein gag/pol
of the nonreplicating murine leukemia virus, GP1 and GP2 of each of the viruses, and the retroviral vec-
tor pQCXIX expressing eGFP (enhanced green fluorescent protein). Transfection was achieved by mixing
equimolar quantities of all three vectors in the presence of calcium phosphate (7) or Lipofectamine 2000
(Invitrogen, USA). HEK-293T cells were incubated with the vector cocktail at 37°C with 5% CO2. Twenty-
four hours posttransfection, medium was exchanged, and supernatant with the released pseudoviruses
was collected 48 h and 72 h posttransfection. The medium containing each of the pseudoviruses was
clarified by centrifugation at 10,000 g and subsequently filtered with a 0.45-mm polyvinylidene difluo-
ride filter (Jetbiofil, China), and pseudovirus particles were further concentrated using a Vivaspin 1,000-
kDa filter (Sartorius, USA). Aliquots were used immediately or stored at 280°C.
Cellular internalization of pseudotyped virus presenting NWHF glycoproteins. HEK-293T cells at
approximately 40% confluence were preincubated with medium containing a serial dilution (from 0.001
to 100 nM) of OKT9 or with 100 nM OKT9-Fab and 50 nM anti-EGFR (negative control) for 30min at 37°C
with 5% CO2 in 48-well plates (CellATTACH Biofil, China). One hundred microliters of the concentrated
solution of pseudovirus particles of JUNV, MACV, CHAV, GTOV, SABV, SABV-L, and LASV (control) in the
presence of the different antibody conditions was added to each well. Cells were incubated for 16 h and
washed with fresh medium. After 48 h of incubation at 37°C with 5% CO2, cells were inspected by wide-
field fluorescence microscopy on an Olympus CKX41 inverted microscope (Olympus, Japan) equipped
with an LCAch N 20/0.40 Php objective (Olympus, Japan), and bright-field and fluorescence images
were acquired with a Q-Color5 digital imaging system (Olympus, Japan). Cells were then fixed with 2%
paraformaldehyde, and the inhibition of internalization was quantified by flow cytometry using a
FACScanto (BD Biosciences, USA) equipped with an argon ion laser (488 nm), with filter settings for GFP
(530/30 nm), and the flow data were analyzed with the software FlowJo 7.6 (BD Biosciences, USA).
Relative internalization was determined as the percentage of cells positive for GFP normalized to cells
treated in the absence of antibodies. The IC50 data were calculated from each pseudovirus dose-
response data set. For this analysis, we used a dose-response model assuming that the log (inhibitor)
versus response curves follow a symmetrical sigmoidal shape. The IC50 of OKT9 for JUNV, MACV, CHAV,
GTOV, SABV, and SABV-L was determined as the concentration that provokes a response halfway
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between the maximal (top) response and the maximally inhibited (bottom) response. We did not include
the estimated IC50 of LASV, because it did not exhibit inhibition in the OKT9 tested concentration range.
The fitting model used is Y = bottom 1 top-bottom)/(11 10(X-LogIC50)), where IC50 is the concentration of
OKT9 that gives a response halfway between bottom and top; and top and bottom are plateaus in the
units of the Y axis. Statistical differences between OKT9, OKT9-Fab, and anti-EGFR compared to non-
treated control conditions were analyzed using nonpaired t test with two tails and assuming different
variances between groups.
Cell labeling with fluorescent transferrin and a fluorescent membrane probe. The fluorescent
labeling of HEK-293T cells with Tf-TMR (Invitrogen, USA) and the lipophilic fluorophore Vybrant DiO cell-
labeling solution (Invitrogen, USA) was performed by following the manufacturer's instructions. Briefly,
HEK-293T cells at 50% confluence and grown in coverslips were incubated with medium containing 100
nM OKT9, 100 nM OKT9-Fab, 100 nM anti-EGFR, or no antibody for 48 h. Medium was exchanged, and
350 ml of 50mg/ml Tf-TMR (red) diluted in medium without serum was added to each well. Cells were
incubated 30 s and washed one time with PBS. After that, cells were fixed with 4% paraformaldehyde for
20min. Cells were washed 3 times for 3min with PBS, and 350 ml of Vybrant DiO (green) cell-labeling so-
lution diluted 1:200 was added and incubated for 20min at 37°C. Next, cells were washed with PBS and
mounted on a slide. Cells were inspected by wide-field fluorescence microscopy on an Olympus IX83
motorized confocal DSU (disk spinning unit) module (Olympus, Japan) equipped with a PlanAPO N 60/
1.42 objective. Bright-field and fluorescence images were acquired with ORCA FLASH 4.0 V2 digital
CMOS (4 MP, 16 bits) (Hamamatsu, Japan) and CellSens Dimensions software (Olympus, Japan). The
green and red image overlay was generated using the ImageJ Merge function.
In vitro inhibition of JUNV infection. A549 cells (ATCC CCL-185) were plated in 24-well plates at a
density of 105 cells per well. After 24 h, the cells were incubated for 1 h with 200 nM OKT9, OKT9-Fab, or
a control IgG (anti-EGFR) or medium alone (control). After incubation, cells were infected for 1 h with
JUNV IV4544 viral strain (15) at a multiplicity of infection (MOI) of 0.01 in the presence of antibodies.
After removing the inoculum, cell monolayers were incubated with the respective antibody-supple-
mented medium or medium alone. The supernatants were harvested 24 h postinfection, and JUNV pro-
duction was titrated by a standard plaque assay in Vero cells.
Quantitative real-time PCR determination of viral load was assessed as follows. A549 monolayers
were harvested, and RNA was extracted using Tri Reagent (Molecular Research Center, USA) according
to the manufacturer’s instructions. cDNA then was generated by use of murine reverse transcriptase M-
MLV (Promega, USA) and random primers (Biodynamics, Argentina). This cDNA was amplified by real-
time PCR using SYBR green complete mix detection (Roche, USA). Real-time PCR was carried out with an
initial incubation at 95°C during 5min, followed by 45 cycles of 30 s at 95°C, 45 s at 60°C, and 30 s at 72°
C and a final step of 5min at 72°C. Amplification plots were analyzed with Bio-Rad software, and the
comparative threshold cycle method was used to determine viral gene expression relative to the b-actin
cellular gene. Primer sequences are the following: Actin Fw, 59-GAGACCTTCAACACCCCAGCC-39; Actin
Rv, 59-GGCCATCTCTTGCTCGAAGTC-39; Z Fw, 59-ATGGGCAACTGCAACGGGGCATC-39; Z Rv, 59-CTATGGT
GGTGGTGCTGTTGGCT-39.
Statistical analysis was carried out using InfoStat software (http://www.infostat.com.ar). Randomized
block analysis of variance (ANOVA) was performed in titration assays, while ANOVA was performed in
RNA quantification assays. In both, statistical significance was assessed at a level of a P value of ,0.05,
followed by Dunnett’s or Duncan’s post hoc test (InfoStat; http://www.infostat.com.ar). Graphs were cre-
ated using GraphPad Prism software (La Jolla, CA; www.graphpad.com).
Crystallographic analysis of the OKT9-Fab. The OKT9-Fab was concentrated to;10mg/ml in 50mM
Tris-HCl, pH 7.5, with an Amicon Ultra-4 10K centrifugal filter device (Millipore, USA) and then filtered using a
0.22-mm centrifuge filter (Corning, USA) (Table 3). A LabTech mosquito crystal nanodispenser TTP robot (TTP
LabTech, UK) was used to evaluate 576 different conditions in a pendant drop vapor diffusion system. The
plates were incubated in an environment without vibrations at approximately 18°C. Several conditions pro-
duced crystals of various qualities, and a MgCl2-containing mother liquor was chosen for optimization. In a
24-well optimization plate (Hampton Research, USA), vapor diffusion/hanging-drop conditions in 1:1 and 1:2
drops of protein to mother liquor were prepared using various concentrations of Tris, MgCl2, and polyethyl-
ene glycol (PEG) 8000. Large, blade-like crystals grew under conditions containing 100mM Tris, 200mM
MgCl2, and 20%, wt/vol, PEG 8000. These crystals were collected and passed through glycerol as a cryoprotec-
tant, mounted on a microloop, and flash frozen into liquid nitrogen for transport. X-ray diffraction data were
obtained at beamline 24-ID-E at the APS synchrotron (Advanced Photon Source, Argonne National
Laboratory). Diffraction patterns were reduced in XDS and then merged and scaled in XSCALE (39). The struc-
ture was phased by molecular replacement using PHASER in the PHENIX suite of crystallographic software
(40) with a chimeric model generated from two antibody Fabs (PDB entries 4Q0X and 4OTX). Following initial
refinement in BUSTER (https://www.globalphasing.com/), final refinement was carried out in PHENIX, with
model building in COOT (41). Visualization of models and structural analyses were performed in PyMOL
(https://pymol.org/2/).
Electron microscopy of OKT9-sTfR1 complexes. Purified OKT9 and sTfR1 were diluted to 10mg/ml
and 2mg/ml, respectively. A 1:1 ratio of diluted OKT9 and sTfR1 was then mixed and further diluted by a
factor of two. OKT9-sTfR1 negative-stained grids were prepared for electron microscopy by placing a
2.5-ml drop of complex onto a glow-discharged ultrathin C film on Lacey Carbon 300 mesh (Ted Pella,
Inc., USA) and washed twice with 2% uranyl acetate. Negative-stain grids were imaged at room tempera-
ture using a Tecnai F30 operating at 300 keV at a magnification of 120,000 on a TVIPS XF-416 camera
with a pixel size of 16mm and a sensor with 4,096 by 4,096 pixels. These settings corresponded to a pixel
size of approximately 2.0 Å/pixel. A total of 5 data sets were collected at various tilt angles to facilitate
Ferrero et al. Journal of Virology












































views of the complex and avoid orientation bias. In addition to zero tilt, data were collected at a tilt of
10, 25, 35, and 45°.
Single-particle analysis of OKT9-sTfR1 complexes. Global contrast transfer function was calculated
using Gctf implemented in RELION 3.0.7 for micrographs in all data sets. Approximately 982 (0° tilt), 946 (10°
tilt), 1,389 (25° tilt), 2,044 (35° tilt), and 909 (45° tilt) particles were manually picked from the respective data
sets. OKT9-sTfR1 particles were extracted in RELION using a 250-pixel box size. After extraction, STAR files
were joined to combine particles from all data sets. Particles were initially classified using K=20 classes and
angular sampling of 5°. Several rounds of 2D classification allowed for removal of poorly aligning particles.
Final 2D classifications were performed using K=4 with a final particle count of 4,191. RELION extracted par-
ticles were also imported into cryoSPARC 2.12.2 for 2D classification. Selected 2D classes containing 5,217
particles were used as inputs for an ab initio reconstruction. The resulting best class and volume containing
3,436 particles were used for homogenous refinement.
ClusPro model generation. The docking model of OKT9-Fab to hTfR1 was performed using the
web server ClusPro docking algorithm (18). This software runs a rigid body docking, followed by a
root mean standard deviations clustering ranked by the number of structures with the lowest
energy and refined by energy minimization to remove steric clashes (18). The structures of OKT9-
Fab and hTfR1 were uploaded to the ClusPro v2.0 server in antibody-antigen mode for docking (42).
The hTfR1 monomeric structure extracted from the PDB entry 3KAS was defined as the ligand, while
the newly determined structure of OKT9-Fab with a modeled Y103 side chain was defined as the re-
ceptor. To minimize the search region for docking, we relied on the 3D density of the complex of
OKT9-hTfR1. Based on this density, we identified the overall region of the hTfR1 apical domain
bound by OKT9. We selected an attraction mask that included hTfR1 surface residues D204-L212,
N348-E350, S368-K371, and K374. We also applied a repulsion mask surrounding this interaction
area on the hTfR1 apical domain that included the following surface residues: V228-L232, Y247-
G252, I277, A340-E343, G351, D352, and M365-T367. For OKT9-Fab, we used a repulsion mask that
excluded the surface residues of the heavy- and light-chain CDRs and the surface residues surround-
ing them. The repulsion mask included light-chain residues D1-C23, L39-K51, L53, I54, G63-G72,
T78-C94, and G105-E219 and the heavy-chain residues Q1-A24, M34, W36-E46, I48, G49, T58, Y60-
S76, T78-A97, and W109-R219. Residues in the attraction and repulsion masks were identified using
PyMOL.
Fit of ClusPro models into 3D density for OKT9-hTfR1 complex. 3D density corresponding to the
final homogenous refinement map was loaded onto Chimera for further analysis. The ectodomain of the
dimeric human transferrin crystal structure (PDB entry 1CX8) was manually placed within the map den-
sity, followed by the fit-in-map function to finalize placement of the structure. Monomeric hTfR1 (PDB
entry 3KAS) and ClusPro inputs were placed using MatchMaker, given the dimer structure as a reference.
All generated ClusPro models were subsequently fit using MatchMaker and 3KAS as a reference and
were later manually inspected for fit onto the 3D density.
Data availability. The coordinates for the structure of OKT9-Fab have been deposited in the
Worldwide Protein Data Bank (wwPDB) with accession code 6WX1.
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